Начало・Списък с акции・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Отворен

СекторЗдравеопазване

6.42 0.16

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.3

Максимум

6.48

Ключови измерители
By Trading Economics
Приходи	36M -3.7M
Продажби	16M 66M
EPS	0.01
Марж на печалбата	-5.67
Служители	416
EBITDA	54M 12M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	-11.68% downside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.1B 2.5B
Предишно отваряне	6.26
Предишно затваряне	6.42

Настроения в новините

By Acuity

100%

320 / 340 Класиране в Healthcare

Maravai LifeSciences Holdings Inc (Class A) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:46 ч. UTC

Maravai LifeSciences Holdings Inc shares are lower during Monday's session, trading below their 20-day moving average with no specific news to explain the decline.

31.07.2026 г., 19:36 ч. UTC

Maravai LifeSciences Holdings Inc. shares are lower today amid broader market volatility, having previously dropped to a session low before partially recovering.

30.07.2026 г., 16:56 ч. UTC

Maravai LifeSciences Holdings Inc shares are gaining amid broader market recovery, with the S&P 500 advancing as investors engage in bargain hunting.

29.07.2026 г., 20:09 ч. UTC

Maravai LifeSciences Holdings Inc shares declined during Wednesday's session, pulling back from earlier gains amid broader market volatility and rising oil prices.

28.07.2026 г., 18:06 ч. UTC

Maravai LifeSciences Holdings Inc is gaining during Tuesday's session, though it pulled back from earlier highs amid broader market pressure in the tech sector.

24.07.2026 г., 19:36 ч. UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market pressures, reflecting declines in the Nasdaq 100 following disappointing earnings from major tech companies.

23.07.2026 г., 09:01 ч. UTC

Maravai LifeSciences Holdings Inc. shares are lower in pre-market trading, continuing a decline since Wednesday's close without significant recovery.

22.07.2026 г., 19:56 ч. UTC

Maravai LifeSciences Holdings Inc. shares are lower today, retracing from earlier highs amid no specific company news. The stock remains above its 20-day moving average.

21.07.2026 г., 19:56 ч. UTC

News

Maravai LifeSciences' TriLink BioTechnologies secures a patent for CleanCap® technology in China, boosting confidence in RNA-based therapies. Shares are higher since Monday's close.

20.07.2026 г., 20:02 ч. UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market declines. The stock hit a session low earlier but has since recovered slightly.

Сравнение с други в отрасъла

Ценова промяна

Maravai LifeSciences Holdings Inc (Class A) Прогноза

Ценова цел

By TipRanks

-11.68% надолу

12-месечна прогноза

Среден 5.67 USD -11.68%

Висок 6 USD

Нисък 5 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Maravai LifeSciences Holdings Inc (Class A) през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Maravai LifeSciences Holdings Inc (Class A) през последните 3 месеца.

Настроение

By Acuity

320 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.